Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:address |
gptkb:31_East_62nd_Street,_New_York,_NY_10065,_USA
|
| gptkbp:CEO |
gptkb:Phillip_L._Gomez
|
| gptkbp:collaboratesWith |
gptkb:U.S._government_agencies
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
countermeasures for biological warfare
|
| gptkbp:focusesOn |
antiviral treatments
|
| gptkbp:foundedYear |
1995
|
| gptkbp:hasCompany |
true
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
SIGA Technologies
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:marketCap |
over $500 million (as of 2023)
|
| gptkbp:notableProduct |
gptkb:TPOXX
gptkb:tecovirimat |
| gptkbp:numberOfEmployees |
approximately 50-100 (as of 2023)
|
| gptkbp:receivedFDAApprovalFor |
gptkb:TPOXX
|
| gptkbp:specializesIn |
smallpox treatment
|
| gptkbp:stockSymbol |
gptkb:SIGA
|
| gptkbp:website |
https://www.siga.com/
|
| gptkbp:bfsParent |
gptkb:MacAndrews_&_Forbes
gptkb:Ronald_Perelman gptkb:Ronald_O._Perelman |
| gptkbp:bfsLayer |
6
|